Life AI Net
首页
资讯库
计算器
目录
周刊
Hot
登录
简体中文
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
首页
资讯库
计算器
目录
周刊
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
登录
首页
资讯库
计算器
目录
More
滚动资讯
FierceBiotech
Pulnovo Medical scores $100M in finance round led by Medtronic
Lonza News
Lonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWS
10x Genomics Blog
Is Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)? - simplywall.st
Brady Corporation
Milwaukee’s Brady Corp Buying Honeywell Division - Seehafer News
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
BioWorld
Pricing standoff leaves Australian patients in limbo
BioWorld
Mabwell turns to Hong Kong to fund ADC ambitions
BioWorld
Xuanzhu shares dip despite phase III ALK inhibitor data
FierceBiotech
Pulnovo Medical scores $100M in finance round led by Medtronic
Lonza News
Lonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWS
10x Genomics Blog
Is Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)? - simplywall.st
Brady Corporation
Milwaukee’s Brady Corp Buying Honeywell Division - Seehafer News
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
BioWorld
Pricing standoff leaves Australian patients in limbo
BioWorld
Mabwell turns to Hong Kong to fund ADC ambitions
BioWorld
Xuanzhu shares dip despite phase III ALK inhibitor data
资讯库
搜索
搜索
最新
最旧
清除
@BioWorld
总数
1062
来源
BioWorld
搜索
--
BioWorld
2026年4月7日
Stipple launches with $100M for novel oncology targets
BioWorld
2026年4月6日
Appointments and advancements for April 6, 2026
BioWorld
2026年4月6日
Financings for April 6, 2026
BioWorld
2026年4月6日
In the clinic for April 6, 2026
BioWorld
2026年4月6日
Other news to note for April 6, 2026
BioWorld
2026年4月6日
Regulatory actions for April 6, 2026
BioWorld
2026年4月6日
Biggest gainers and losers for March 30-April 3, 2026
BioWorld
2026年4月6日
Holiday notice
BioWorld
2026年4月2日
Money raised by biopharma
BioWorld
2026年4月2日
Biopharma money raised: Jan. 1-April 2, 2026
BioWorld
2026年4月2日
BioWorld and Nasdaq stock indices
BioWorld
2026年4月2日
Biopharma money raised by month in 2026 (US$M)
BioWorld
2026年4月2日
Regulatory actions for April 2, 2026
BioWorld
2026年4月2日
Financings for April 2, 2026
BioWorld
2026年4月2日
Lipocine phase III with oral brexanolone bombs in PPD
BioWorld
2026年4月2日
Holiday notice
BioWorld
2026年4月2日
Amgen synthesizes new GTPase KRAS (G12D mutant) inhibitors
BioWorld
2026年4月2日
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
上一页
7 / 59
下一页